Basics of Chimeric Antigen Receptor (CAR) Immunotherapy presents the latest on how T cell adoptive immunotherapy has progressed in its ultimate goal of curing metastatic malignant cancers. Recent clinical data obtained with checkpoint receptor blockade inhibitors and chimeric antigen receptor (CAR) therapy has been especially promising, thus generating renewed hope that we may be on the verge of finally curing cancer. Over the years, huge progress has been made in controlling several stage IV metastasized cancers through the clinical application of checkpoint receptor inhibitory drugs and CAR-Therapy that has seen unprecedented interest in the immunotherapy field.
- Presents the first book to provide a basic understanding of chimeric antigen receptor (CARs) design, production and clinical application protocols
- Provides unique authority as the editor has worked directly with CARs
- Discusses the challenges encountered in actual clinical trials and how these challenges can be overcome
- Includes a full chapter on various challenges researchers should expect to encounter in the CAR-therapy field
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
2. Components and design of Chimeric Antigen Receptors (CARs)
3. scFv cloning, vectors and CAR production in laboratory for preclinical application
4. Production of CAR-T cells for clinical application
5. Challenges and opportunities to improve CAR-TE cell therapy
Mumtaz Y. Balkhi, Ph.D., Chief Scientific Officer, Immunotherapeutic Lab (ITL); faculty appointments as Assistant Professor in the Hematology-Oncology Division, Department of Medicine, Tufts University School of Medicine. Assistant Professor (cooperating), Division of Biomedical Sciences, Orono Maine, USA